1Stewart TL, Ralston SH. Role of genetic factors in the pathogenesis of osteoporosis[J]. J Endocrinol, 2000, 166(2): 235-245.
2Maricic M. The role ofzoledronic acid in the management of osteoporosis[J]. Clin Rheumatol, 2010, 29(10): 1079-1084.
3Rakel A, Boucher A, Ste-Marie LG. Role of zoledronic acid in the prevention and treatment of osteoporosis[J]. ClinInterv Aging, 2011, 6: 89-99.
4Levine JP. Zoledronic acid reduces osteoporotic fractures and ensures medication compliance for 1 year[J]. Postgrad Med, 2010, 122(3): 248-250.
5Delmas PD, Munoz F, Black DM, et al. Effects of yearly zoledronic acid 5 mg on bone tumover markers and relation of P1NP with fracture reduction in postmenopausal women with osteoporosis[J]. J Bone Miner Res, 2009, 24(9): 1544-1551.
6Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis[J]. N Engl J Med, 2007, 356(18): 1809-1822.
7Lyles KW, Col6n-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture[J]. N Engl J Med, 2007, 357(18): 1799-1809.
8Stewart TL, Ralston SH.Role of genetic factors in the patho- genesis of osteoporosis[J].J Endocrinol, 2000,166 (2) : 235- 245.
9Briot K,Cortet B,Thomas T,et al.2012 update of French guidelines for the pharmacological treatment of postmen. Pausal osteoporosis[J].Joint Bone Spine, 2012,79 (3) : 304- 313.
